VTX3232 meets safety, biomarker, and efficacy endpoints in Phase 2a Parkinson’s study

Ventyx Biosciences, Inc.

Steady-state CSF and plasma drug levels exceeded IC90 for NLRP3 inhibition by ≥3-fold over 24h.
VTX3232 treatment significantly reduced NLRP3-related biomarkers IL-1β, IL-18, IL-6, and hsCRP in plasma and CSF.
Clinically meaningful improvements in MDS-UPDRS Parts II and III observed; all patients reported subjective improvement.
No drug-related adverse events; all mild/moderate, attributed to procedures. No serious AEs.
Company planning double-blind placebo-controlled Phase 2 trial in Parkinson's and potentially Alzheimer's.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.